Literature DB >> 10490210

Classification and behavior of canine mammary epithelial neoplasms based on life-span observations in beagles.

S A Benjamin1, A C Lee, W J Saunders.   

Abstract

As part of a study of the effects of low-level radiation, 1,343 Beagles, including 671 males and 672 females, were evaluated over their full lifetime for the occurrence of mammary neoplasia; there were 139 control males and 138 control females and 532 irradiated males and 534 irradiated females. All nodules found in surgical specimens or at necropsy were evaluated histologically. The overall incidence, metastasis and recurrence rates, and contribution to mortality of mammary neoplasms were determined. Based on this unique opportunity to correlate morphologic characteristics with ultimate biological behavior of all mammary tumors in a defined canine population, we propose a histogenetically based reclassification of epithelial mammary tumors. Of the 672 female dogs, 70.8% (476) had at least one mammary neoplasm; 60.7% (408) had more than one. Two male dogs had mammary neoplasms. Of 1,639 mammary carcinomas in the 672 females, 18.7% (307) were classified as ductular carcinomas (arising from the small interlobular or intralobular ductules), whereas 80.7% (1,322) were classified as adenocarcinomas of other histogenetic origin. Of 73 fatal carcinomas, ductular carcinomas accounted for 48 fatalities (65.8%), whereas other adenocarcinomas accounted for only 20 fatalities (27.4%). Radiation had no effect on this ratio. Ductular carcinomas also had a higher rate of metastasis than did adenocarcinomas. Existing classifications of mammary carcinomas do not recognize the characteristic morphologic features, the degree of malignancy, and the prognostic importance of these ductular carcinomas. Metastasis rates did not differ between simple and complex carcinomas or between those lesions and adenocarcinomas in mixed tumors. True carcinosarcomas metastasized more frequently (100%, or 5/5) than did adenocarcinomas in mixed tumors (34.4%, or 22/64), emphasizing the importance of not lumping these tumors under the classification of malignant mixed tumors.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10490210     DOI: 10.1354/vp.36-5-423

Source DB:  PubMed          Journal:  Vet Pathol        ISSN: 0300-9858            Impact factor:   2.221


  24 in total

1.  In Vitro Validation of the Hippo Pathway as a Pharmacological Target for Canine Mammary Gland Tumors.

Authors:  Samantha Guillemette; Charlène Rico; Philippe Godin; Derek Boerboom; Marilène Paquet
Journal:  J Mammary Gland Biol Neoplasia       Date:  2017-08-18       Impact factor: 2.673

2.  Metastatic canine mammary carcinomas can be identified by a gene expression profile that partly overlaps with human breast cancer profiles.

Authors:  Robert Klopfleisch; Dido Lenze; Michael Hummel; Achim D Gruber
Journal:  BMC Cancer       Date:  2010-11-09       Impact factor: 4.430

3.  Uterine carcinosarcoma (malignant mixed Müllerian tumor): case report in a goat and literature review.

Authors:  Brieuc Cossic; Jacqueline A Hill; Marta Cercone; Teresa Southard
Journal:  J Vet Diagn Invest       Date:  2018-10-21       Impact factor: 1.279

4.  Nuclear morphometry in relation to lymph node status in canine mammary carcinomas.

Authors:  G De Vico; P Maiolino; M Cataldi; G Mazzullo; B Restucci
Journal:  Vet Res Commun       Date:  2007-02-05       Impact factor: 2.816

5.  Evaluation of adverse effects in tamoxifen exposed healthy female dogs.

Authors:  Wanessa L F Tavares; Gleidice E Lavalle; Mariana S Figueiredo; Aline G Souza; Angelica C Bertagnolli; Fernando A B Viana; Paulo R O Paes; Rubens A Carneiro; Guilherme A O Cavalcanti; Marilia M Melo; Geovanni D Cassali
Journal:  Acta Vet Scand       Date:  2010-12-22       Impact factor: 1.695

6.  The hyaluronan synthesis inhibitor 4-methylumbelliferone exhibits antitumor effects against mesenchymal-like canine mammary tumor cells.

Authors:  Teruyoshi Saito; Tamura Dai; Ryuji Asano
Journal:  Oncol Lett       Date:  2013-01-10       Impact factor: 2.967

7.  Canine mammary mixed tumours: a review.

Authors:  Geovanni Dantas Cassali; Angélica Cavalheiro Bertagnolli; Enio Ferreira; Karine Araújo Damasceno; Conrado de Oliveira Gamba; Cecília Bonolo de Campos
Journal:  Vet Med Int       Date:  2012-10-21

8.  Sialyl Lewis x expression in canine malignant mammary tumours: correlation with clinicopathological features and E-Cadherin expression.

Authors:  Salomé S Pinho; Augusto J F Matos; Célia Lopes; Nuno T Marcos; Júlio Carvalheira; Celso A Reis; Fátima Gärtner
Journal:  BMC Cancer       Date:  2007-07-06       Impact factor: 4.430

9.  Expression and significance of CHIP in canine mammary gland tumors.

Authors:  Huanan Wang; Xu Yang; Yipeng Jin; Shimin Pei; Di Zhang; Wen Ma; Jian Huang; Hengbin Qiu; Xinke Zhang; Qiuyue Jiang; Weidong Sun; Hong Zhang; Degui Lin
Journal:  J Vet Med Sci       Date:  2015-07-09       Impact factor: 1.267

10.  Canine Mammary Cancer Stem Cells are Radio- and Chemo- Resistant and Exhibit an Epithelial-Mesenchymal Transition Phenotype.

Authors:  Lisa Y Pang; Alejandro Cervantes-Arias; Rod W Else; David J Argyle
Journal:  Cancers (Basel)       Date:  2011-03-30       Impact factor: 6.575

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.